

# Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non small cell lung cancer

Information for the public

Published: 1 July 2015

[www.nice.org.uk](http://www.nice.org.uk)

## What has NICE said?

Nintedanib (Vargatef), given with a drug called docetaxel, is recommended. It is a possible treatment for people with a certain type (adenocarcinoma) of locally advanced, metastatic or locally recurrent non-small-cell lung cancer that has got worse after previous chemotherapy.

## What does this mean for me?

If you have locally advanced, metastatic or locally recurrent non-small-cell lung cancer of adenocarcinoma histology, and your doctor thinks that nintedanib (with docetaxel) is the right treatment, you should be able to have the treatment on the NHS.

Nintedanib should be available on the NHS within 3 months of the guidance being issued.

## Why has NICE said this?

NICE looks at how well treatments work in relation to how much they cost compared with other treatments available on the NHS.

Nintedanib was recommended because it works better than other treatments available on the NHS. Although it also costs more than other treatments, this was justified by the benefits it provided when the special considerations were applied.

## The condition and the treatment

Lung cancer is grouped into 2 main types depending on how it looks under the microscope: small-cell lung cancer and non-small-cell lung cancer. Cancer that is described as being locally advanced or metastatic has spread to the surrounding tissues or other parts of the body. When it is described as locally recurrent, it means that it has come back again in the lungs.

Nintedanib (Vargatef) is an anticancer drug. It works by stopping the cancer growing.

NHS Choices ([www.nhs.uk](http://www.nhs.uk)) may be a good place to find out more.

## Sources of advice and support

- British Lung Foundation, 03000 030 555 (BLF helpline), [www.blf.org.uk](http://www.blf.org.uk)
- Cancer Research UK, 0808 800 4040, [www.cancerresearchuk.org/about-cancer](http://www.cancerresearchuk.org/about-cancer)
- Macmillan Cancer Support, 0808 808 0000, [www.macmillan.org.uk](http://www.macmillan.org.uk)
- Roy Castle Lung Cancer Foundation, 0333 323 7200, [www.roycastle.org](http://www.roycastle.org)

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-1314-5

## Accreditation

